ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / KMDA / dividends
PRTA (26) MNPR (27) BLSM (42) FTH (29) ⌘ Pro Terminal →

Kamada Ltd. (KMDA) Dividend Safety Gauge & 10-Year DRIP Compounder

$7.70 -3.14% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.64

Kamada Ltd. (KMDA) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $458.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KMDA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KMDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Kamada Ltd. (NASDAQ: KMDA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $7.70 (-3.14% 1D, market cap $458.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KMDA ranks #312 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KMDA compare to PRTA and MNPR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KMDA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PRTA (Prothena Corporation plc) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $455.9M) and MNPR (Monopar Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -17.4%, cap $482.7M). Among the 5-stock peer group, KMDA leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KMDA?
▼

For Kamada Ltd. (KMDA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #312 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.64 (-0.76%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510049
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D
Cash (12)Whales (8)SEC (13)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4% Base Target
$10 Bull$7 Base$6 Bear
📬 FREE KMDA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KMDA)Realized 20D OHLCV Swing Band: ±5.5%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY KMDA SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0.3% FCF Margin ($12.8M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit7/20 pts (-13 pt drag)

Macro rate sensitivity & RSI-14 (49.7) create a -13 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
57
Grade C$7.84-2.9% Next Q
Q2 (-2Q)
54
Grade C-$7.61+4.3% Next Q
Q3 (-1Q)
52
Grade C-$7.94-3% Next Q
Current
49
Grade D$7.70-5.4% Hist 90D α
Trajectory: C (57) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KMDA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KMDA currently carries a cautious 49/100 (D) rating due to Macro Regime Fit (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.19) and Max Pain ($8.09) forces dealer call-delta covering toward $9.82.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KMDA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KMDA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 49%NO 51%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KMDA)

  • ✓Walkthrough of KMDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KMDA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.12%📐 HORIZONTAL RANGE
2026-11-02O $8.00H $8.00L $7.70C $7.70VOL 65.8K
RES: $9.69SUP: $6.64SMA50: $8.19SMA200: $8.02
$9.11$8.50$7.88$7.27$6.66RES $9.69SUP $6.64$7.702026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KMDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KMDA Butterfly Map → + Track KMDA →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KMDA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KMDA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KMDA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KMDA)

Health Care Rank #312 of 1016 ⚔️ PRTA vs KMDA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KMDA vs. PRTA, MNPR, BLSM, FTH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kamada Ltd. (KMDA) ranks #312 by composite RQD confidence (49/100, grade D) and #464 by equity capitalization ($458.8M). Within this direct 5-issuer industry benchmark cohort, KMDA leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. KMDA currently leads its immediate peer cohort in composite quantitative strength at 49/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KMDA ACTIVE
Kamada Ltd.
D 49/100 — — — -3.14% $458.8M Benchmark Subject
PRTA
Prothena Corporation plc
E 26/100 — — -35.0% -4.62% $455.9M /prta-vs-kmda →
MNPR
Monopar Therapeutics Inc.
E 27/100 — — -17.4% -2.21% $482.7M /mnpr-vs-kmda →
BLSM
BlossomHill Therapeutics Inc.
D- 42/100 — — — -9.60% $483.4M /blsm-vs-kmda →
FTH
Faeth Therapeutics Inc.
E 29/100 — — -35.0% -0.32% $484.5M /fth-vs-kmda →

2. KMDA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Kamada Ltd. (KMDA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $458.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. KMDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KMDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Kamada Ltd. (NASDAQ: KMDA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $7.70 (-3.14% 1D, market cap $458.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KMDA ranks #312 in composite RQD confidence.

How does KMDA compare to PRTA and MNPR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KMDA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PRTA (Prothena Corporation plc) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $455.9M) and MNPR (Monopar Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -17.4%, cap $482.7M). Among the 5-stock peer group, KMDA leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KMDA?

For Kamada Ltd. (KMDA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #312 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KMDA trading relative to its 50-day, 200-day, and 52-week technical levels?

KMDA last traded at $7.70 (-3.14% on volume of 47,517 shares), positioning the stock -5.98% below its 50-day simple moving average ($8.19) and -3.99% below its 200-day simple moving average ($8.02). Across its 52-week range of $6.55 to $9.35, KMDA sits at the 41.1% percentile with a 14-day RSI of 49.7 (NEUTRAL RANGE) and an implied next-earnings move of ±5.5% ($7.28 to $8.12).

KMDA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does KMDA pay a dividend and is it safe?

Kamada Ltd. (KMDA) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: KMDA RQD Cockpit KMDA 12M Forecast KMDA Earnings & Move KMDA Dividends & DRIP KMDA Insiders & 13F KMDA Whale Options KMDA Profit Sankey KMDA News & Why
ROARABLE RATING BRIEF • RQD 49/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

KMDA — Kamada Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:16:06Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, KMDA scores 49 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are as follows:

  • Fundamental Cash Engine: 12 / 20 (ROIC 0%; FCF yield 0%). The rating's cash-generation pillar is weak, and the source data shows no measured return on invested capital or free cash flow yield. For a prospective investor, this means the business is not currently demonstrating the cash-earning power that typically supports valuation.
  • Whale 13F Flow: 8 / 20 (institutional accumulation and options positioning). This is a below-midpoint reading, suggesting limited evidence of large institutional conviction in the source data.
  • Insider Conviction: 9 / 20 (SEC Form 4 and Congressional PTR cluster flow). The reading indicates modest insider-side confidence signals.
  • Macro Regime Fit: 7 / 20 (beta 1.0; sector sensitivity). A beta of 1.0 means the stock is rated as moving in line with the broader market, and the low pillar score signals weak positioning for the prevailing regime per the rating.
  • Forensic Balance Sheet: 13 / 20 (Altman Z 2.5; Piotroski F 6/9; debt/equity 0.5). This is the strongest pillar, indicating the balance sheet is comparatively the most defensible part of the thesis.

Taken together, the rating frames KMDA as a name where the balance sheet offers some stability, but cash generation, institutional support, and insider signals are not supportive. Upside drivers would need to come from improvements in cash returns or a shift in institutional positioning; the source data does not identify a valuation anchor (P/E and EV/EBITDA are not available in source data) against which to weigh the stock's $7.95 price. This is an educational summary of the rating, not personalized advice.

Open Questions

  • What are the reported revenue, operating income, net income, and free cash flow figures, and what is the period-over-period trend?
  • What are the company's specific products, approved indications, and key biosimilar programs referenced in the Stifel note?
  • What is the outcome of the November 9, 2026 earnings and management call?
  • What is the analyst consensus rating and price target distribution, and who are the major institutional or insider holders?
  • What does the company's cash runway and debt maturity profile look like given a 0% FCF yield?

KMDA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kamada Ltd. (KMDA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KMDA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KMDA Bull vs. Bear Conversation Board — What's Your Call at $7.70?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KMDA 🐻 50% BEARISH CONVICTION
1. Pick Your Side on KMDA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $8.59 (+8.1%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is KMDA (D • RQD 49/100) a Buy at $7.95?

Welcome to the KMDA (Kamada Ltd.) Roar Pit. Current RQD Composite is 49/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $6.36 (-20.0%)
Spot @ $7.95

Pump the brakes on KMDA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on KMDA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Kamada Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $10.18 (+28.1%)
Spot @ $7.95

KMDA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on KMDA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $7.95 (52-wk range $6.55 - $9.35), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%